Discussion
After receiving positive regulatory feedback from the U.S. Food and Drug Administration (FDA), Oculis is planning to expand clinical testing of its experimental therapy privosegtor as a potential treatment for acute relapses in people with multiple sclerosis (MS). Privosegtor is already being investigated as a treatment for…